Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01551030 · ClinicalTrials.gov registry record · Phase 2
Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
A Phase 2 study of Metastatic Transitional Cell Carcinoma of the Urothelium, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 5
- Study locations
NCT01551030 is a Phase 2 study of Metastatic Transitional Cell Carcinoma of the Urothelium that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 19 participants. The trial reports 5 study locations across 2 states.
The verdict
NCT01551030, a Phase 2 study of Metastatic Transitional Cell Carcinoma of the Urothelium, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to learn what effects, good and/or bad, Buparlisib has on advanced urothelial cancer. Buparlisib is a pill that works by shutting down some of the signals in cancer cells that make tumors grow. It is being tested in patients in research studies such as this one. As of 2010, more than 80 patients with various types of cancer have received treatment with Buparlisib in research studies. This clinical research study is divided into two parts. The goal of the first part of this study is to learn if the study drug Buparlisib can shrink or slow the growth of cancer in patients with urothelial tumors. The goal of the second part of this study is to learn if the study drug Buparlisib can shrink or slow the growth of urothelial tumors in patients known to have certain genetic alterations that cause these types of tumors. The study doctor will inform the patient which part of the study is currently enrolling participants. Participants in both parts of the study will receive the same treatment and tests. The safety of this drug will also be studied in both parts. The physical state, changes in the size of the tumor, and laboratory findings taken while on-study will help us decide if Buparlisib is safe and effective.
Conditions Studied
Interventions
- DRUG Buparlisib
Study Locations (5)
New York
- Memorial Sloan-Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan-Kettering Cancer Center at Mercy Medical Center - Rockville Centre
- Memoral Sloan Kettering Cancer Center@Phelps - Sleepy Hollow
New Jersey
- Memorial Sloan-Kettering at Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-03 |
| Est. Completion | 2020-09-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01551030
The ClinicalTrials.gov registry entry for NCT01551030 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Transitional Cell Carcinoma of the Urothelium appearing as the primary indexed condition, and to 1 intervention - of which Buparlisib is the first listed.
NCT01551030 reports 5 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01551030 about?
NCT01551030 is a clinical study titled "Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium". The purpose of this study is to learn what effects, good and/or bad, Buparlisib has on advanced urothelial cancer. Buparlisib is a pill that works by shutting down some of the signals in cancer cells that make tumors grow. It is being tested in patients in research studies such as this one. As of 20...
What is the current status of trial NCT01551030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-03. Estimated completion is 2020-09-02.
What conditions does trial NCT01551030 study?
This clinical trial studies the following conditions: Metastatic Transitional Cell Carcinoma of the Urothelium.
What interventions are being tested in trial NCT01551030?
The interventions under investigation include: Buparlisib (DRUG).
Who is sponsoring clinical trial NCT01551030?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01551030 being conducted?
This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.